NCT04100447View on ClinicalTrials.gov

A Study to Evaluate the Safety, Tolerability and Efficacy of LB1148 for Subjects Undergoing Elective Bowel Resection

PHASE1CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

November 5, 2018

Primary Completion Date

March 20, 2020

Study Completion Date

December 1, 2020

Conditions
AdhesionsIleus
Interventions
DRUG

Tranexamic Acid

A total of 700 mL of study drug should be completely consumed orally 2-12 hours prior to surgery as a split dose; 350 mL 6-12 hours prior to surgery and the remaining 350 mL 2-6 hours prior to surgery.

Trial Locations (1)

90301

Centinela Hospital Medical Center, Inglewood

All Listed Sponsors
lead

Ronald Hurst, MD, FACS

OTHER

NCT04100447 - A Study to Evaluate the Safety, Tolerability and Efficacy of LB1148 for Subjects Undergoing Elective Bowel Resection | Biotech Hunter | Biotech Hunter